Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With Statin for ACS Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.
Also called NCT07736313
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT07736313
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07736313. Non-randomized; no masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2028-09-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With Statin for ACS Patients
- Condition
- Acute Coronary Syndromes
- Intervention (Drug)
- PCSK9 inhibitor plus rosuvastatin 20 mg tab
- Intervention (Drug)
- Rosuvastatin 20 Mg Oral Tablet
- Lead sponsor
- Assiut University
Record details
- Record id
cardio:ct-nct07736313- Content hash
e37ddf2b4f51e08d7ce31d4669f3f005e1125b013e3f431bcf815c2e275868a0